129 related articles for article (PubMed ID: 31975801)
1. Adjunctive Therapy With Second-Generation Antipsychotics: The New Standard for Treatment-Resistant Depression?
Thase ME
Focus (Am Psychiatr Publ); 2016 Apr; 14(2):180-183. PubMed ID: 31975801
[TBL] [Abstract][Full Text] [Related]
2. Adverse Effects of Second-Generation Antipsychotics as Adjuncts to Antidepressants: Are the Risks Worth the Benefits?
Thase ME
Psychiatr Clin North Am; 2016 Sep; 39(3):477-86. PubMed ID: 27514300
[TBL] [Abstract][Full Text] [Related]
3. Treating depression with adjunctive antipsychotics.
Mulder R; Hamilton A; Irwin L; Boyce P; Morris G; Porter RJ; Malhi GS
Bipolar Disord; 2018 Nov; 20 Suppl 2():17-24. PubMed ID: 30328223
[TBL] [Abstract][Full Text] [Related]
4. Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - Results from a European multicenter study.
Dold M; Bartova L; Kautzky A; Serretti A; Porcelli S; Souery D; Mendlewicz J; Montgomery S; Zohar J; Kasper S
Eur Neuropsychopharmacol; 2018 Dec; 28(12):1305-1313. PubMed ID: 30446357
[TBL] [Abstract][Full Text] [Related]
5. Evaluating antidepressant treatment prior to adding second-line therapies among patients with treatment-resistant depression.
Hassan AK; Farmer KC; Brahm NC; Neas BR
Int J Clin Pharm; 2016 Apr; 38(2):429-37. PubMed ID: 26935957
[TBL] [Abstract][Full Text] [Related]
6. Treatment-resistant bipolar disorder.
Gitlin M
Mol Psychiatry; 2006 Mar; 11(3):227-40. PubMed ID: 16432528
[TBL] [Abstract][Full Text] [Related]
7. [Second generation antipsychotics in bipolar depression: a new therapeutic option?].
Llorca PM
Encephale; 2011 Dec; 37 Suppl 3():S209-13. PubMed ID: 22212877
[TBL] [Abstract][Full Text] [Related]
8. The use of adjunctive antipsychotics to treat depression in UK primary care.
Lamy FX; Saragoussi D; Johnson ME; Guiraud-Diawara A; Jørgensen KT; Loze JY; Maguire A
Curr Med Res Opin; 2017 May; 33(5):891-898. PubMed ID: 28277876
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials.
McGirr A; Vöhringer PA; Ghaemi SN; Lam RW; Yatham LN
Lancet Psychiatry; 2016 Dec; 3(12):1138-1146. PubMed ID: 28100425
[TBL] [Abstract][Full Text] [Related]
10. Combined treatment with atypical antipsychotics and antidepressants in treatment-resistant depression: preclinical and clinical efficacy.
Rogóż Z
Pharmacol Rep; 2013; 65(6):1535-44. PubMed ID: 24553002
[TBL] [Abstract][Full Text] [Related]
11. Major Depressive Disorder (MDD) and Schizophrenia- Addressing Unmet Needs With Partial Agonists at the D2 Receptor: A Review.
Mallet J; Gorwood P; Le Strat Y; Dubertret C
Int J Neuropsychopharmacol; 2019 Oct; 22(10):651-664. PubMed ID: 31406978
[TBL] [Abstract][Full Text] [Related]
12. Severe depression: is there a best approach?
Sonawalla SB; Fava M
CNS Drugs; 2001; 15(10):765-76. PubMed ID: 11602003
[TBL] [Abstract][Full Text] [Related]
13. [Clinically relevant drug interactions with new generation antidepressants and antipsychotics].
Eckert A
Ther Umsch; 2009 Jun; 66(6):485-92. PubMed ID: 19496045
[TBL] [Abstract][Full Text] [Related]
14. Brexpiprazole as an augmentation agent to antidepressants in treatment resistant major depressive disorder.
Cha DS; Luo X; Ahmed J; Becirovic L; Cha RH; McIntyre RS
Expert Rev Neurother; 2019 Sep; 19(9):777-783. PubMed ID: 31389279
[No Abstract] [Full Text] [Related]
15. Patterns of psychotropic medication use in inpatient and outpatient psychiatric settings in Saudi Arabia.
Alosaimi FD; Alhabbad A; Abalhassan MF; Fallata EO; Alzain NM; Alassiry MZ; Haddad BA
Neuropsychiatr Dis Treat; 2016; 12():897-907. PubMed ID: 27143891
[TBL] [Abstract][Full Text] [Related]
16. Do depressed patients on adjunctive atypical antipsychotics demonstrate a better quality of life compared to those on antidepressants only? A comparative cross-sectional study of a nationally representative sample of the US population.
Al-Ruthia YS; Hong SH; Solomon D
Res Social Adm Pharm; 2015; 11(2):228-40. PubMed ID: 25023755
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.
Tundo A; de Filippis R; Proietti L
World J Psychiatry; 2015 Sep; 5(3):330-41. PubMed ID: 26425446
[TBL] [Abstract][Full Text] [Related]
18. Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis.
Zhou X; Keitner GI; Qin B; Ravindran AV; Bauer M; Del Giovane C; Zhao J; Liu Y; Fang Y; Zhang Y; Xie P
Int J Neuropsychopharmacol; 2015 May; 18(11):pyv060. PubMed ID: 26012350
[TBL] [Abstract][Full Text] [Related]
19. [Systematic review to evaluate the efficacy, acceptability and safety of second-generation antipsychotics for the treatment of unipolar and bipolar depression.].
Amato L; Vecchi S; Barbui C; Cruciani F; D'Amico R; Del Giovane C; Minozzi S; Mitrova Z; Saulle R; Davoli M
Recenti Prog Med; 2018 Oct; 109(10):474-486. PubMed ID: 30394408
[TBL] [Abstract][Full Text] [Related]
20. Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature.
Wright BM; Eiland EH; Lorenz R
Pharmacotherapy; 2013 Mar; 33(3):344-59. PubMed ID: 23456734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
